Glaukos Corporation $GKOS Shares Purchased by Rhumbline Advisers

Rhumbline Advisers increased its stake in Glaukos Corporation by 12.7% in Q2, owning 159,283 shares worth $16.45 million. Insider transactions included CFO Alex Thurman and COO Joseph Gilliam selling shares. Glaukos stock rose 0.9% to $106.33. Analysts upgraded price targets, with Citigroup and BTIG Research giving 'buy' ratings. Glaukos reported Q3 earnings beating estimates, with revenue up 38.1% year-over-year.

Rhumbline Advisers boosted its stake in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 12.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 159,283 shares of the medical instruments supplier's stock after buying an additional 17,929 shares during the period. Rhumbline Advisers owned 0.28% of Glaukos worth $16,452,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Park Place Capital Corp increased its stake in shares of Glaukos by 68.4% in the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier's stock worth $41,000 after acquiring an additional 162 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of Glaukos by 0.4% in the second quarter. Harbor Capital Advisors Inc. now owns 39,305 shares of the medical instruments supplier's stock valued at $4,060,000 after purchasing an additional 173 shares during the period. AQR Capital Management LLC increased its position in Glaukos by 2.6% during the first quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier's stock worth $766,000 after purchasing an additional 198 shares during the last quarter. Profund Advisors LLC raised its stake in Glaukos by 13.9% during the second quarter. Profund Advisors LLC now owns 2,822 shares of the medical instruments supplier's stock worth $291,000 after purchasing an additional 345 shares during the period. Finally, Avior Wealth Management LLC boosted its holdings in Glaukos by 12.3% in the 2nd quarter. Avior Wealth Management LLC now owns 3,800 shares of the medical instruments supplier's stock valued at $393,000 after purchasing an additional 416 shares during the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Glaukos

In related news, CFO Alex R. Thurman sold 315 shares of Glaukos stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $105.00, for a total value of $33,075.00. Following the completion of the transaction, the chief financial officer owned 50,488 shares in the company, valued at approximately $5,301,240. The trade was a 0.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Joseph E. Gilliam sold 19,340 shares of the company's stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $90.00, for a total transaction of $1,740,600.00. Following the sale, the chief operating officer directly owned 92,366 shares in the company, valued at approximately $8,312,940. The trade was a 17.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 5.80% of the stock is owned by corporate insiders.

Glaukos Stock Up 0.9%

Shares of NYSE GKOS opened at $106.33 on Friday. Glaukos Corporation has a 52-week low of $73.16 and a 52-week high of $163.71. The business's 50 day moving average is $86.82 and its two-hundred day moving average is $91.89. The firm has a market cap of $6.11 billion, a price-to-earnings ratio of -69.05 and a beta of 0.81. The company has a quick ratio of 4.69, a current ratio of 5.51 and a debt-to-equity ratio of 0.09.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.11. The business had revenue of $133.54 million during the quarter, compared to analysts' expectations of $122.55 million. Glaukos had a negative return on equity of 7.53% and a negative net margin of 18.65%.The company's revenue was up 38.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.28) earnings per share. Glaukos has set its FY 2025 guidance at EPS. Research analysts predict that Glaukos Corporation will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GKOS. Citigroup raised their price target on shares of Glaukos from $110.00 to $113.00 and gave the stock a "buy" rating in a report on Thursday, October 30th. BTIG Research raised their target price on Glaukos from $104.00 to $116.00 and gave the stock a "buy" rating in a research note on Thursday, October 30th. The Goldman Sachs Group initiated coverage on Glaukos in a research report on Wednesday, October 1st. They issued a "buy" rating and a $103.00 target price on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Glaukos in a research note on Wednesday, October 8th. Finally, Zacks Research downgraded Glaukos from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 15th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $119.08.

Read Our Latest Report on Glaukos

Glaukos Company Profile

(Free Report)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

Should You Invest $1,000 in Glaukos Right Now?

Before you consider Glaukos, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.

While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here